Offered through our partner laboratory, Adgyl Lifesciences
Eurofins Advinus, through a specialized partner laboratory Adgyl Lifesciences, provides a robust portfolio of validated in vivo pharmacology models to support preclinical research in central nervous system (CNS) disorders.
These services are designed to help pharmaceutical and biotech companies evaluate the efficacy, safety, and pharmacodynamic profiles of novel therapies across a wide range of neurological and psychiatric conditions.
Covering key CNS domains such as Parkinson’s disease, depression, anxiety, epilepsy, cognitive dysfunction, and more, our models are grounded in both classical and advanced methodologies ensuring reproducible, translational, and regulatory-aligned outcomes.
Capabilities Offered via Adgyl Lifesciences include
Parkinson’s Disease Models
- Haloperidol-Induced Catalepsy (Rat): Evaluates extrapyramidal side effects relevant to antipsychotic drugs.
- 6-OHDA-Induced Nigrostriatal Lesion (Rat): Models motor impairment and degeneration in Parkinsonian conditions.
- Levodopa-Induced Dyskinesia (Rat): Assesses motor side effects in hemiparkinsonian rats under L-DOPA treatment.
- MPTP-Induced Parkinsonism (Mouse – C57BL/6J): Mimics dopaminergic neurodegeneration and PD-like pathology.
Antidepressant & Anxiolytic Activity
- Tail Suspension Test (Mice): Screens antidepressant activity via behavioral despair analysis.
- Forced Swim Test (Mice & Rats): Assesses immobility behavior as a depression index.
- Novelty-Suppressed Feeding (Rat): Measures anxiety-driven feeding delay.
- Marble Burying Test (Mice): Behavioral assay for evaluating anxiolytic effects.
- Social Interaction Test: Explores sociability and anxiety in rodents.
Motor Function & Behavioral Assessment
- Rotarod Test: Evaluates motor coordination and balance impairments.
- Open Field Test: Measures spontaneous activity and anxiety-related behaviors.
- Morris Water Maze / Y Maze / Elevated Plus Maze: Cognitive and anxiety tests assessing memory, learning, and decision-making.
- Head Twitch Response: Indicates serotonergic modulation and psychotropic drug activity.
Cognition Models
- Novel Object Recognition Test (NORT): Non-invasive cognitive function assessment for memory and recognition studies.
Epilepsy & Neuroprotection
- Pentylenetetrazole (PTZ)-Induced Seizures: Acute model for screening anticonvulsant drugs.
- DOI-Induced Head Twitch Response: Used for evaluating serotonergic and hallucinogenic drug effects.
- Blood-Brain Barrier (BBB) Integrity Studies: Crucial for understanding neurotherapeutic delivery and safety.
Safety Pharmacology
- Irwin’s Test Battery (Mice & Rats): Comprehensive neurobehavioral screening to evaluate general CNS side effects and pharmacological profiles.
Why Partner with Us for CNS Research?
- Extensive Disease Model Portfolio: Covers a wide spectrum of neurological and psychiatric disorders.
- Regulatory-Ready Protocols: Available as GLP or non-GLP studies to support preclinical and IND-enabling phases.
- Customizable Study Designs: Protocols tailored to therapeutic targets, dosing regimens, and combination strategies.
- High Scientific Rigor: All models follow validated protocols with robust QC measures for reproducibility.
- Integrated Services: Combine behavioral studies with PK/PD, biomarker analysis, and safety pharmacology.
Frequently Asked Questions (FAQs)
How do I choose the right CNS model for my drug candidate?
Our scientific experts will evaluate your therapeutic area, mechanism of action, and research goals to recommend the most suitable in vivo model and study design.
Are these models suitable for GLP and IND-enabling studies?
Yes. All studies can be conducted under GLP or non-GLP conditions, depending on your development stage. Our models are validated to meet international regulatory standards.
Can studies be tailored for specific drug mechanisms or targets?
Absolutely. We offer flexible and adaptive protocols to support dosing strategies, biomarkers, combination therapies, and other customized requirements.
How do you ensure reproducibility and reliability of the data?
Each study follows standardized protocols with rigorous QA/QC oversight, validated methodologies, and repeatable outcomes across replicates and time points.
What are the typical timelines for CNS studies?
Most acute models are completed within 4–6 weeks, while chronic models may extend up to 12 weeks. A project-specific timeline is provided at initiation.
Accelerate Your CNS Drug Discovery Program
Access proven in vivo models for CNS disorders through Adgyl Lifesciences, under the scientific leadership of Eurofins Advinus. From model selection to regulatory-ready data, we partner with you at every step to accelerate development of breakthrough therapies.
Get in touch with our CNS experts today to discuss your study requirements.
Partner for your CNS research